Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | APEX1 | P27695 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | THPO | P40225 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | RGS12 | O14924 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377145 | 1.00 | KDM4E (0.61) | KDM4EHSD17B10TDP1MAPTPOLB | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL29382155 | 0.77 | GAA (1.00) | KDM4EHSD17B10TDP1MAPTPOLB | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL36348 | 0.77 | GAA (1.00) | KDM4EHSD17B10TDP1MAPTPOLB | |
| SCHEMBL6377861 | 0.76 | HSD17B10 (0.55) | KDM4EHSD17B10TDP1MAPTPOLB | |
| SCHEMBL6374835 | 0.76 | HSD17B10 (0.55) | KDM4EHSD17B10TDP1MAPTPOLB | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL8214151 | 0.75 | GAA (0.96) | KDM4EHSD17B10TDP1MAPTPOLB | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL8214147 | 0.75 | GAA (0.96) | KDM4EHSD17B10TDP1MAPTPOLB | |
| SCHEMBL4957230 | 0.75 | CES1 (0.61) | MAPTHPGDGAALMNAHIF1A | |
| SCHEMBL22982989 | 0.74 | KDM4E (0.72) | KDM4EHSD17B10TDP1MAPTPOLB | |
| SCHEMBL31618868 | 0.74 | KDM4E (0.72) | KDM4EHSD17B10TDP1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-03 | — | — | US | disclosed |
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-03 | — | — | US | disclosed |
| EP-1063888-A1 | NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS | The Regents of the University of California (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1063888-A1 | NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS | The Regents of the University of California (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999048371-A1 | NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999048371-A1 | NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | DDO, DNTT, DSTYK | KDM4E 255/4885HSD17B10 539/4885TDP1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.